Compositions and methods for treating kabuki syndrome and related disorders

1. A method of treating Kabuki syndrome (KS) in a subject in need thereof, comprising administering to the subject a ketogenic composition in an amount sufficient to produce a physiologically acceptable ketosis in the subject and for a duration sufficient to treat KS in the subject.

2. A method of promoting a treatment for Kabuki syndrome (KS) in a subject in need thereof, wherein the treatment comprises administering a ketogenic composition in an amount sufficient to produce a physiologically acceptable ketosis in the subject and for a duration sufficient to promote treatment of KS in the subject.

3. The method of claim 1 , wherein the ketogenic composition comprises a ketogenic diet.

4. The method of claim 3 , wherein the ketogenic diet comprises a diet in which about 2% to about 15% by weight of its caloric content is carbohydrates, about 60% to about 90% by weight of its caloric content is fat, and about 8% or less by weight of its caloric content is protein.

5. The method of claim 1 , wherein the ketogenic composition comprises a nutritionally balanced ketogenic diet.

6. The method of claim 5 , wherein the nutritionally balanced ketogenic diet comprises a diet in which about 2% to about 15% by weight of its calcific content is carbohydrates, about 60% to about 90% by weight of its caloric content is fat, and about 8% to about 30% by weight of its caloric content is protein.

7. The method of claim 5 , wherein the nutritionally balanced ketogenic diet comprises a 4:1 ratio of caloric fat content to caloric protein content.

8. The method of claim 1 , wherein the ketogenic composition comprises a ready-to-drink beverage, powdered beverage formulation, nutritional or dietary supplement selected from the group consisting of gelatin capsule or tablet, suspension, parenteral solution, or a food product formulated for human consumption.

9. The method of claim 1 , wherein the ketogenic composition comprises at least one ketogenic compound selected from the group consisting of

i) a ketogenic amino acid selected from the group consisting of isoleucine, leucine, tryptophan, lysine, phenylalanine, tyrosine, aspartate β-semialdehyde, β-aspartylphosphate, saccharopine, α-aminoadipate δ-semialdehyde, and α-aminoadipate;

ii) an immediate precursor of a ketogenic amino acid selected from the group consisting of α-ketoglutarate, indole, α-ketobutarate, L-histadinol, phenylpyruvate, 4-hydroxyphenylpyruvate, methyltetrahydrofolate, α-keto-β-methylvalerate, and α-ketoisovalerate;

iii) an amino acid increasing molecule selected from the group consisting of a glutamate dehydrogenase, a valine aminotransferase, an arginosuccinate lyase, a tyrosine transaminase, an aromatic amino acid transaminase, a tryptophan synthase, and a histidinol dehydrogenase;

iv) a medium chain triglyceride;

v) a short chain fatty acid; and

vi) combinations thereof.

10. The method of claim 1 , wherein the ketogenic composition comprises at least one agent that promotes open chromatin states at one or more target genes in the subject.

11. The method of claim 10 , wherein the agent decreases the level and/or activity of a histone deacetylase protein in the subject.

12. The method of claim 11 , wherein the histone deacetylase protein is selected from the group consisting of histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2), histone deacetylase 3 (HDAC3), histone deacetylase 4 (HDAC4), histone deacetylase 5 (HDAC5), histone deacetylase 6 (HDAC6), histone deacetylase 7 (HDAC7), histone deacetylase 8 (HDAC8), histone deacetylase 9a (HDAC9a), histone deacetylase 9b (HDAC9b), histone deaceytlase 9c (HDAC9c), histone deaceytlase 10 (HDAC10), histone deacetylase 11 (HDAC11), SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.

13. The method of claim 10 , wherein the agent increases the level of H3Kme4 in the subject.

14. The method of claim 10 , wherein the agent decreases deacetylation of and/or increases trimethylation of lysine 4 of histone 3 in the subject.

15. The method of claim 10 , wherein the at least one agent is selected from the group consisting of:

i) D-β-hydroxybutyrate;

ii) a salt of D-β-hydroxybutyrate;

iii) a metabolic precursor of D-β-hydroxybutyrate;

iv) an ester or polyester of D-β-hydroxybutyrate; and

v) combinations thereof.

16. The method of claim 10 , wherein the at least one agent is selected from the group consisting of

i) (S-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide (AR-42);

ii) 2-Propylpentanoic acid (valproic acid);

iii) N′-hydroxy-N-phenyl-octanediamide (vorinostat); and

iv) 5H-dibenz[b,f]azepine-5-carboxamide (carbamazepine).

17. The method of claim 1 , wherein the ketogenic composition is administered at least once daily.

18. The method of claim 1 , wherein the ketogenic composition is administered as part of a daily treatment regimen that lasts for at least two weeks.

19. The method of claim 1 , wherein the ketogenic composition is administered as part of a daily treatment regimen that lasts for at least 6 months.

20. The method of claim 1 , wherein the physiologically acceptable ketosis produced is such that the total concentration of β-hydroxybutyrate in the blood of the subject is raised to between 0.5 and 10 mM.

21. The method of claim 1 , wherein the total concentration of β-hydroxybutyrate in the blood is raised to between 1 and 6 mM.

22. The method of claim 1 , wherein a urinary excretion level of β-hydroxybutyrate is from about 5 to about 200 mg/dL.

23. The method of claim 1 , wherein the subject is a human.

24. The method of claim 1 , wherein the subject has, or is suspected of having, a redox imbalance.

25. The method of claim 1 , further comprising determining whether the subject has a lysine (K)-specific methyltransferase 2D (KMT2D) gene mutation, a lysine (K)-specific demethylase 6A(KDM6A) gene mutation, or both.